Given the association between reduced Nurr1 expression and these changes in dopaminergic neurons, beside anti-synucleinopathy therapy, increasing Nurr1 expression has been suggested as a promising therapeutic target for Parkinson disease [28]. Here, NR4A2 is linked to Parkinson disease.